PRMT6 is aberrantly overexpressed in multiple human cancers—including lung [79], liver [80], colon [81], gastric [82], endometrial [47,83], and prostate cancer—and its dysregulation is associated with aberrant methylation patterns and poor clinical prognosis. The gene discussed is PRMT6; the disease is cancer.